

## D-ribose, an overlooked player in type 2 diabetes mellitus?

SU Tao<sup>1,2</sup> & HE RongQiao<sup>1\*</sup>

<sup>1</sup>State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China;

<sup>2</sup>University of Chinese Academy of Sciences, Beijing 100049, China

Received December 11, 2013; accepted January 7, 2014; published online January 20, 2014

**Citation:** Su T, He RQ. D-ribose, an overlooked player in type 2 diabetes mellitus? *Sci China Life Sci*, 2014, 57: 361, doi: 10.1007/s11427-014-4614-5

Type 2 diabetes mellitus is a metabolic disorder that is characterized by high blood glucose due to either insulin resistance or insulin deficiency [1]. A direct correlation between D-glucose and diabetic complications has long been established, and is the focus of most research in this field. In contrast, D-Ribose has been overlooked so far as a potential risk player in the development of diabetes.

Recently published reports found abnormally high levels of D-ribose in the urine of diabetic patients [2]. Elsewhere, intravenous administration of D-ribose resulted in a decrease in blood D-glucose, concomitantly with an increase in the level of glycated serum proteins [3]. It is known that administration of high dose of D-ribose rapidly glycates proteins *in vivo* and *in vitro* [4–6], which results in the production of high levels of advanced glycation end products. D-glucose, in contrast, cannot be used to the same effect, even under identical conditions [7].

Therefore, as we hypothesized, dysfunction of the metabolism of D-ribose may play a role involving the development of complications of type 2 diabetes mellitus, and it is feasible that D-ribose could be used as a biomarker for type 2 diabetes mellitus. That is, diabetics suffer from dysfunction of energy metabolism, involving not only D-glucose, but also D-ribose. This viewpoint for D-ribose in diabetes is based on these observations: (i) Diabetics display abnormal increases in the level of uric D-ribose; (ii) Raised levels of D-ribose result in increased ribosylation activity, in the result of which more advanced glycation end products accumulate in cells; and (iii) D-ribose could be used as a

new biomarker for type 2 diabetes mellitus, as it is easily measured in the urine of diabetic patients.

We suggest that this novel view of type 2 diabetes mellitus deserves further and detailed investigation, both at the level of basic and clinical research, to clarify whether and how D-ribose and its metabolism are related with diabetic complications.

*This work was supported by the National Basic Research Program of China (2012CB911004, 2010CB912303) and the National Natural Science Foundation of China (31270868, 31200601).*

- 1 Kumar V, Fausto N, Abbas AK. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Saunders, 2005, 1194–1195
- 2 Su T, Xin L, He YG, Wei Y, Song YX, Li WW, Wang XM, He RQ. The abnormally high level of uric D-ribose for type-2 diabetics. *Prog Biochem Biophys*, 2013, 40: 816–825
- 3 Han CS, Lu Y, Wei Y, Liu Y, He RQ. D-Ribose induces cellular protein glycation and impairs mouse spatial cognition. *PLoS ONE*, 2011, 6: e24623
- 4 Wei Y, Chen L, Chen J, Ge L, He RQ. Rapid glycation with D-Ribose induces globular amyloid-like aggregations of BSA with high cytotoxicity to SH-SY5Y cells. *BMC Cell Biol* 2009, 10:10
- 5 Chen L, Wei Y, Wang XQ, He RQ. Ribosylation rapidly induces  $\alpha$ -synuclein to form highly cytotoxic molten globules of advanced glycation end products. *PLoS ONE*, 2010, 5: e9052
- 6 Chen L, Wei Y, Wang XQ, He RQ. D-Ribosylated Tau forms globular aggregates with high cytotoxicity. *Cell Mol Life Sci*, 2009, 66: 2559–2571
- 7 Wei Y, Han CS, Zhou J, Liu Y, Chen L, He RQ. D-Ribose in glycation and protein aggregation. *Biochim Biophys Acta-GS*, 2012, 1820: 488–494

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

\*Corresponding author (email: rongqiaohe@163.com)